Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Mirum Pharmaceuticals (NASDAQ: MIRM) announced it will present new data at the EASL International Liver Congress 2026, highlighting its leadership in rare cholestatic liver diseases and expansion into new areas like HDV. Presentations will include late-breaking results from the Phase 2b VISTAS study of volixibat in primary sclerosing cholangitis (PSC) and the Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with data on LIVMARLI® (maralixibat) in progressive familial intrahepatic cholestasis (PFIC). The company emphasizes its commitment to addressing unmet patient needs and advancing therapies for rare liver diseases.
MIRM: Clinical and commercial catalysts drive growth, with major pipeline and BD milestones ahead
Mirum Pharmaceuticals (MIRM) is experiencing strong clinical and commercial momentum, driven by LIVMARLI sales growth, positive pivotal data for PSC, and strategic pipeline expansion. The company anticipates key readouts for volixibat and Brelovitug, which are expected to open significant market opportunities. This outlook is based on insights from RBC Capital Markets Global Healthcare Conference 2026.
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock
Mirum Pharmaceuticals director Saira Ramasastry sold 2,000 shares for $218,940 on May 15, 2026, as part of a Rule 10b5-1 trading plan, while concurrently acquiring 2,000 shares through option exercise. Despite a subsequent stock decline, the company reported strong Q1 2026 revenue but missed EPS targets due to acquisition costs. Mirum also announced a $600 million convertible senior notes offering to refinance existing debt and for general corporate purposes.
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity
Mirum Pharmaceuticals, Inc. director Saira Ramasastry engaged in an exercise-and-sell transaction on May 15, 2026, acquiring 2,000 shares via stock options at $23.51 per share and immediately selling them at $109.47 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on September 18, 2025. Following the trades, her direct common stock holdings in the company were 0 shares.
Mirum Pharmaceuticals (NASDAQ: MIRM) sells $600M 2032 converts, to refinance 2029 notes
Mirum Pharmaceuticals (NASDAQ: MIRM) has issued $690 million in 0.00% Convertible Senior Notes due 2032, including an over-allotment option, with estimated net proceeds of $671.6 million. The company plans to use approximately $475 million and 3.2 million shares to exchange $237.2 million of its 2029 convertible notes, with the remaining funds for general corporate purposes and potential acquisitions. These zero-coupon notes have an initial conversion price of $138.94 per share, representing a 30% premium over the stock price on May 12, 2026, and aim to shift debt to a longer-dated instrument while potentially leading to future equity dilution.
What Mirum Pharmaceuticals (MIRM)'s Volixibat PSC Trial Win and $600M Notes Deal Means For Shareholders
Mirum Pharmaceuticals recently announced positive Phase 2b trial results for volixibat in primary sclerosing cholangitis and completed a $600 million convertible note offering, while also raising its 2026 net product sales guidance. These developments are expected to reshape the company’s growth narrative, adding volixibat as a potential second key product alongside Livmarli, despite a significant quarterly net loss. The note offering reinforces the company's funding runway, supporting the continued development and commercialization of its pipeline.
What Mirum Pharmaceuticals (MIRM)'s Volixibat PSC Trial Win and $600M Notes Deal Means For Shareholders
Mirum Pharmaceuticals recently secured a win with its VISTAS Phase 2b trial for volixibat in primary sclerosing cholangitis and completed a $600 million convertible note offering. This trial success supports plans for future FDA submission, strengthening the company's rare-disease growth strategy beyond its existing drug, Livmarli. Despite a significant quarterly net loss, Mirum Pharmaceuticals also raised its 2026 net product sales guidance, highlighting the importance of converting pipeline milestones into commercial successes.
Assessing Mirum Pharmaceuticals (MIRM) Valuation After A Strong Year And Recent Share Price Pullback
Mirum Pharmaceuticals (MIRM) has seen a significant stock increase over the last year, despite a recent pullback. The company is currently valued at approximately US$6.8 billion and is considered undervalued by some analysts with a fair value estimate of $129.73, driven by a strong pipeline and future growth potential in rare disease therapies. Investors are encouraged to assess the underlying data, risks, and rewards to determine if the stock presents a buying opportunity.
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29
The article reports that the price target for Mirum Pharmaceuticals (MIRM) has been increased by 16.75%. The new price target is set at $149.29.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals announced inducement grants to 12 new employees under Nasdaq Listing Rule 5635(c)(4), consisting of non-qualified stock options to purchase 22,950 shares of common stock and 31,300 restricted stock units (RSUs). These awards, approved by the Compensation Committee, are designed to incentivize new hires and will vest over several years based on continued employment. Mirum Pharmaceuticals specializes in rare diseases, with a portfolio of approved products and a pipeline of investigational medicines.
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last?
Mirum Pharmaceuticals (MIRM) experienced a 5.1% increase in its stock price, outperforming the S&P 500's 0.2% gain on the day. This positive movement is attributed to strong earnings estimate revisions for the upcoming quarter and full year, with the Zacks Consensus Estimate for next quarter's earnings rising 1.4% in the last 30 days. The article discusses whether this upward momentum will continue based on its Zacks Rank and favorable valuation metrics.
Latham Advises on Mirum Pharmaceuticals Convertible Senior Notes Offering
Latham & Watkins LLP advised the initial purchasers in Mirum Pharmaceuticals Inc.'s US$600 million offering of 0.00% convertible senior notes due 2032. The private placement to qualified institutional buyers is scheduled to settle on May 15, 2026. Mirum also granted the initial purchasers an option to buy an additional US$90 million aggregate principal amount of notes.
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals announced the reporting of inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The article, published on MarketScreener, mentioned this update amidst other recent news for the company, including analyst target adjustments and Q1 2026 earnings results. Financial data and company-specific news are also highlighted within the content.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. announced inducement grants to 12 new employees on May 11, 2026. These awards, approved by the Compensation Committee, consist of non-qualified stock options for 22,950 shares and 31,300 restricted stock units (RSUs), aligning with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $106.17 and vest over four years, while RSUs vest over three years, both contingent on continued employment.
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals announced the pricing of a $600.0 million offering of 0.00% convertible senior notes due 2032 through a private placement. The company plans to use a portion of the net proceeds, estimated at $583.8 million, to refinance approximately $237.2 million of its existing 4.00% convertible senior notes due 2029, involving both cash and shares of common stock. The remaining proceeds will be allocated for general corporate purposes, including potential acquisitions.
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD
Mirum Pharmaceuticals (MIRM) stock reached an all-time high of $112.47, reflecting a significant 152.31% increase over the past year and investor confidence, despite being unprofitable with an EPS of -$15.17. The company recently priced $600 million in convertible senior notes and reported strong Q1 2026 revenue of $159.9 million, leading Baird to raise its price target to $129.
Mirum Pharmaceuticals Prices $600 Million Private Debt Offering
Mirum Pharmaceuticals has priced a $600 million private debt offering consisting of 2.75% Exchangeable Senior Notes due 2030, with an additional $90 million option for initial purchasers. The notes are unsecured obligations and will bear interest semi-annually, convertible into cash, Mirum common stock, or a combination thereof, contingent on specific conditions and Mirum's election. The company intends to use the net proceeds to repurchase existing convertible notes, repay debt under its credit facility, and for general corporate purposes.
Mirum Pharmaceuticals prices $600M senior notes
Mirum Pharmaceuticals has announced the pricing of $600 million in senior notes. This financial move is a significant development for the company.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026. Both events will feature company fireside chats, which will be webcast live and made available for replay on Mirum's corporate website. The company aims to highlight its rare disease portfolio and pipeline to investors.
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals announced the pricing of a $600.0 million offering of 0.00% convertible senior notes due 2032 in a private placement. The company expects to use the net proceeds, estimated at $583.8 million, for general corporate purposes and to refinance a portion of its 2029 convertible notes by exchanging approximately $237.2 million aggregate principal amount of these notes for $475.0 million in cash and approximately 3.2 million shares of its common stock. The initial conversion price for the new notes is $138.94 per share, representing a 30.0% premium over the last
Mirum Pharmaceuticals Announces Private Placement of Convertible Senior Notes to Qualified Institutional Buyers
Mirum Pharmaceuticals has announced a private placement of convertible senior notes to qualified institutional buyers, as defined by Rule 144A of the Securities Act of 1933. The company plans to use the net proceeds for general corporate purposes, including R&D, working capital, and potential acquisitions or strategic investments. The specific terms of the notes, such as interest rate, conversion rate, and maturity date, will be determined at the time of pricing.
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by State of New Jersey Common Pension Fund D
The State of New Jersey Common Pension Fund D significantly reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 58.2% in the fourth quarter, selling 17,940 shares and retaining 12,860 shares valued at $1.02 million. This comes as analysts maintain a "Moderate Buy" rating with an average price target of $136.42, despite the company reporting mixed quarterly results with a revenue beat but a larger-than-expected EPS loss. Insider selling, including by the SVP and CFO, also occurred as the stock traded around $106.17.
Mirum Pharmaceuticals to Participate in Upcoming May 2026 Investor Conferences
Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation in two investor conferences in May 2026: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19 and the RBC Capital Markets Global Healthcare Conference on May 20. The company, which specializes in rare diseases, will hold fireside chats at both events, accessible via live webcast from its investor relations website.
Number of shareholders of Mirum Pharmaceuticals, Inc. – TRADEGATE:08D
This article provides details on the number of shareholders for Mirum Pharmaceuticals, Inc. (TRADEGATE:08D). It highlights market data provided by ICE Data Services and reference data from FactSet. The information is presented within the TradingView platform context.
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last?
This article discusses Mirum Pharmaceuticals (MIRM) stock, which saw a 5.1% increase, and questions whether this upward trend will continue. The piece likely analyzes factors contributing to the recent stock movement and potential future performance.
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates
Mirum Pharmaceuticals, Inc. (MIRM) announced its Q1 earnings, reporting a loss per share that was slightly higher than anticipated by analysts. Despite the loss, the company successfully exceeded revenue estimates, indicating strong sales performance during the quarter.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced its Q1 2026 earnings, reporting a miss on EPS expectations but raising its full-year revenue guidance to $660 million to $680 million due to strong performance in its rare liver disease franchise and the recent acquisition of zolergosertib for fibrodysplasia ossificans progressiva (FOP). The company highlighted significant progress in expanding its rare liver disease business with promising clinical readouts for elixirat in PSC and berlivatig in hepatitis delta, alongside the strategic addition of zolergosertib to its rare genetic disease portfolio, which has an accepted NDA with priority review. Mirum expects to become operating cash flow positive next year, driven by its existing commercial medicines and upcoming pipeline advancements.
Mirum Pharmaceuticals (MIRM) Posts Huge US$790 Million Loss Challenging Bullish Profitability Narrative
Mirum Pharmaceuticals (MIRM) reported a significant Q1 2026 loss of US$790.2 million, with a basic EPS loss of US$13.43, despite revenue reaching US$159.9 million. This massive loss challenges the bullish narrative that anticipates revenue growth and a return to profitability within three years. Both bullish and bearish perspectives are evaluating whether this quarter is an outlier or indicative of ongoing execution risks due to R&D and SG&A spending.
Mirum's Q1 earnings & revenues beat estimates, 2026 view raised
Mirum Pharmaceuticals reported better-than-expected Q1 earnings and revenues. The company also raised its full-year 2026 revenue guidance.
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $142 From $128, Maintains Outperform Rating
RBC Capital has increased its price target for Mirum Pharmaceuticals (NASDAQ: MIRM) to $142, up from the previous $128. The firm has concurrently maintained its "Outperform" rating on the stock. This adjustment reflects RBC Capital's updated outlook on the company's financial prospects and market position.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta - Slideshow (NASDAQ:MIRM)
Mirum Pharmaceuticals, Inc. (MIRM) has published a slide deck discussing its topline clinical results for primary sclerosing cholangitis and hepatitis delta. This article, provided by SA Transcripts, highlights the release of this important data by Mirum Pharmaceuticals.
Mirum Pharmaceuticals Q1 2026 Earnings Call Transcript
Mirum Pharmaceuticals reported strong Q1 2026 results, raising its full-year revenue guidance to $660M–$680M due to robust LIVMARLI sales and international performance. The company is strategically expanding its rare liver disease business through positive clinical readouts for volixibat in PSC and brelovitug in hepatitis delta, and has licensed zolegorsertib for FOP, targeting a late 2026 launch if approved. Mirum plans to expand its commercial team to support these new launches, projecting operating cash flow positivity in 2027 and GAAP profitability by 2028 despite current elevated operating expenses due to acquisition costs.
Bluejay buy drives Mirum (Nasdaq: MIRM) to $790M Q1 net loss
Mirum Pharmaceuticals (Nasdaq: MIRM) reported a Q1 2026 net loss of $790.2 million, primarily driven by a one-time $726.3 million acquired in-process R&D charge related to its Bluejay Therapeutics acquisition. Despite this loss, product sales grew to $159.9 million, up from $111.6 million in Q1 2025, fueled by Livmarli and its bile acid medicines. The company maintains $420.6 million in unrestricted cash, cash equivalents and investments and continues to advance its late-stage pipeline including volixibat and brelovitug.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta - Slideshow (NASDAQ:MIRM)
Mirum Pharmaceuticals, Inc. (MIRM) discussed its topline clinical results for treatments in Primary Sclerosing Cholangitis and Hepatitis Delta, presenting a slide deck in conjunction with this event. The company reported a Q1 2026 EPS of -$1.09, missing estimates by $0.73, while revenue of $159.88M beat estimates by $6.83M, representing a 43.28% year-over-year increase.
Earnings call transcript: Mirum Pharmaceuticals Q1 2026 results reveal strong revenue growth
Mirum Pharmaceuticals reported strong Q1 2026 revenue of $159.9 million, exceeding forecasts despite a significant EPS miss due to one-time acquisition costs. The company raised its full-year 2026 sales guidance to $660 million-$680 million, driven by robust performance of LIVMARLI and strategic expansion into rare liver and genetic diseases. While GAAP profitability is projected for 2028, investor confidence led to a 1.5% stock price increase after the earnings release, reflecting optimism about future growth and pipeline advancements, including the addition of zolegorsertib for FOP.
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Mirum Pharmaceuticals (NASDAQ: MIRM) shares rallied after its VISTAS Phase 2b study for volixibat, an investigational treatment for cholestatic pruritus in primary sclerosing cholangitis, met its primary endpoint by significantly reducing itching. The company also announced a pre-New Drug Application meeting with the FDA for summer 2026 and will present full results in May. Additionally, its brelovitug drug in the AZURE-1 study showed strong antiviral activity against chronic hepatitis delta virus.
A Look At Mirum Pharmaceuticals (MIRM) Valuation After Positive VISTAS Phase 2b Volixibat Results
Mirum Pharmaceuticals (MIRM) is in focus after its VISTAS Phase 2b trial for volixibat met its primary endpoint, leading to strong stock performance. Despite a significant year-to-date increase, the company is still considered undervalued, with a narrative fair value of $129.73 and a DCF model suggesting a fair value of $350.69. The valuation hinges on successful late-stage trials and ongoing performance of existing treatments.
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium
Mirum Pharmaceuticals (MIRM) shares rose 10% after its investigational drug volixibat met the primary endpoint in a mid-stage trial for Primary Sclerosing Cholangitis (PSC), a rare liver disease. The drug significantly reduced cholestatic pruritus, a debilitating itching symptom. Mirum plans to submit a New Drug Application in the second half of 2026 and expects further data for primary biliary cholangitis in Q1 2027, leading to a surge in retail investor optimism for a potential buyout.
MIRM SEC Filings - Mirum Pharmaceuticals 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Mirum Pharmaceuticals (MIRM) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. Stock Titan offers AI-powered summaries, impact scoring, and sentiment analysis for these documents to help investors quickly understand key details. Recent filings cover topics such as a merger agreement, private placement, and insider transactions, providing insight into the company’s regulatory disclosures and financial activities.
MIRM Stock Jumps As HDV Data Sends Analysts Scrambling Higher
Mirum Pharmaceuticals Inc. (MIRM) stock surged more than 12% following strong Phase 2b clinical trial results for brelovitug in chronic hepatitis delta virus (HDV). The drug demonstrated 100% virologic response in a key dosing arm, leading analysts from H.C. Wainwright, Baird, and Stifel to raise their price targets. Upcoming catalysts include VISTAS data for volixibat and Q1 2026 earnings, making MIRM a significant focus for biotech traders.
Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial
Mirum Pharmaceuticals announced that its Phase 2b VISTAS trial for volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, significantly reducing pruritus. The company plans to submit a New Drug Application (NDA) to the U.S. FDA in the second half of 2026 and expects topline data for volixibat in primary biliary cholangitis in Q1 2027. This development positions volixibat as a potential first-approved therapy for cholestatic pruritus in PSC, expanding Mirum's presence in cholestatic liver diseases.
Volixibat eases cholestatic itch in PSC trial for Mirum (NASDAQ: MIRM)
Mirum Pharmaceuticals announced positive results from its VISTAS Phase 2b study of volixibat for primary sclerosing cholangitis (PSC), showing significant relief of cholestatic itch. The drug achieved a 2.72-point improvement on the Adult ItchRO scale compared to 1.08 for placebo. Mirum plans a pre-NDA meeting with the FDA in summer 2026 and aims for an NDA submission in the second half of 2026, positioning volixibat as a potential first treatment for this condition, despite gastrointestinal side effects like diarrhea.
Mirum Pharmaceuticals' Volixibat Meets Primary Endpoint in VISTAS Phase 2b for PSC Itch
Mirum Pharmaceuticals announced that its drug volixibat successfully met the primary endpoint in the VISTAS Phase 2b study for treating pruritus in patients with Primary Sclerosing Cholangitis (PSC). The study showed a statistically significant reduction in itch for patients receiving volixibat, alongside a clinically meaningful response in over half of the treated patients and a reduction in serum bile acids. The company plans a pre-NDA meeting with the FDA in summer 2026, with an NDA submission targeted for the second half of 2026.
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Mirum Pharmaceuticals announced that its VISTAS Phase 2b study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant and clinically meaningful reduction in cholestatic pruritus. The company plans a pre-NDA meeting with the FDA in summer 2026 and expects to submit an NDA in the second half of 2026. Full results will be presented at the EASL International Liver Congress 2026.
Mirum Pharmaceuticals stock hits all-time high at 109.29 USD
Mirum Pharmaceuticals Inc. stock has reached an all-time high of $109.29, marking a 139.66% increase over the past year. This milestone is supported by strong revenue growth and positive clinical trial results for its investigational drugs, though InvestingPro's Fair Value analysis suggests the stock may be overvalued. Analysts have reiterated positive ratings and increased price targets due to successful Phase 2b studies.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Mirum Pharmaceuticals announced it will host an investor call on May 4, 2026, to share topline results from its VISTAS study of volixibat for primary sclerosing cholangitis (PSC). The call will provide an update on the company's investigational medicine pipeline, which includes volixibat and other treatments for rare diseases. Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines.
Mirum Pharmaceuticals to Announce Volixibat Primary Sclerosing Cholangitis VISTAS Study Results on May 4, 2026
Mirum Pharmaceuticals will host an investor call on May 4, 2026, to reveal the topline results from their VISTAS study of Volixibat for primary sclerosing cholangitis. During the call, the company will present detailed findings and key data points on the effects of Volixibat on individuals with this chronic bile duct disease. This event will provide investors and interested parties with an in-depth understanding of the study's outcomes.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Mirum Pharmaceuticals (Nasdaq: MIRM) will host an investor call on May 4, 2026, at 8:30 a.m. ET to announce topline results from its VISTAS study of volixibat for primary sclerosing cholangitis (PSC). The company, a leader in rare diseases, focuses on developing breakthrough medicines and has an existing portfolio of commercial products and a robust clinical pipeline. Investors can access the call via conference lines or a webcast available on Mirum's corporate website.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Mirum Pharmaceuticals will host an investor call on May 4, 2026, to share topline results from its VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC). The call will be accessible via phone and webcast. Mirum is a rare disease company with a global portfolio of approved products and a pipeline of investigational medicines.
Pictet Asset Management Holding SA Purchases 35,997 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Pictet Asset Management Holding SA increased its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 6.7% in the fourth quarter, purchasing an additional 35,997 shares and now owning 1.12% of the company, valued at $45.6 million. Despite this institutional buying, Mirum Pharmaceuticals has seen insider selling, with COO Peter Radovich and SVP Jolanda Howe selling shares worth a combined total of over $1.9 million. Analysts currently have a "Moderate Buy" consensus rating for Mirum with an average target price of $121.75, although the company recently missed EPS estimates while exceeding revenue expectations.
